Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned an average recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $24.1538.

CMPS has been the topic of several analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Morgan Stanley restated an “overweight” rating and set a $17.00 target price on shares of Compass Pathways in a research note on Tuesday, July 7th. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Royal Bank Of Canada boosted their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen raised Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th.

Compass Pathways Stock Down 0.6%

Shares of NASDAQ:CMPS opened at $12.35 on Friday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -3.92 and a beta of 2.47. The company has a 50 day moving average of $12.35 and a two-hundred day moving average of $8.84. Compass Pathways has a 52-week low of $3.83 and a 52-week high of $15.40. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. As a group, analysts forecast that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Institutional investors and hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC lifted its holdings in shares of Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after purchasing an additional 1,200 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the last quarter. Conservest Capital Advisors Inc. increased its position in Compass Pathways by 24.6% in the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after buying an additional 5,000 shares during the period. Persistent Asset Partners Ltd bought a new stake in Compass Pathways in the fourth quarter valued at $38,000. Finally, Raymond James Financial Inc. lifted its position in Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after purchasing an additional 6,228 shares during the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.